BiotechTube

MACI

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chondral Defect

Conditions

Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of Knee

Trial Timeline

Oct 24, 2018 → Jun 1, 2027

NCT ID
NCT03588975

About MACI

MACI is a phase 3 stage product being developed by Vericel for Chondral Defect. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03588975. Target conditions include Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect.

What happened to similar drugs?

0 of 1 similar drugs in Chondral Defect were approved

Approved (0) Terminated (0) Active (1)
🔄autologous cultured chondrocytes on porcine collagen membraneVericelPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03588975Phase 3Recruiting

Competing Products

1 competing product in Chondral Defect

See all competitors
ProductCompanyStageHype Score
autologous cultured chondrocytes on porcine collagen membraneVericelPhase 3
41